Share This Page
Drugs in ATC Class D11AH
✉ Email this page to a colleague
Drugs in ATC Class: D11AH - Agents for dermatitis, excluding corticosteroids
| Tradename | Generic Name |
|---|---|
| ASTAGRAF XL | tacrolimus |
| TACROLIMUS | tacrolimus |
| PROGRAF | tacrolimus |
| PROTOPIC | tacrolimus |
| >Tradename | >Generic Name |
ATC D11AH dermatitis non-corticosteroid agents: market dynamics and patent landscape
The patent landscape for ATC D11AH (agents for dermatitis, excluding corticosteroids) is driven by (1) high share of legacy topical small molecules with sporadic entrants, (2) formulation and method-of-use patenting concentrated around vehicles, keratin/plaque penetration, and anti-inflammatory/immunomodulatory pharmacology, and (3) periodic regulatory filings that extend IP through new strengths, new delivery systems (gels/creams/foams/patches), and device-adjacent claims. Commercially, the class is characterized by fragmented, indication-siloed demand across atopic dermatitis, seborrheic dermatitis, contact dermatitis, and eczema-like conditions, with pricing and access influenced by payer policies and generic substitution velocity once patents and exclusivities clear.
Because ATC D11AH is a sub-class and the boundaries “excluding corticosteroids” vary by label and formulation classification, a precise, product-level patent estate build requires mapping each labeled active ingredient and strength to its US FDA/NDA/ANDA/BLA portfolio and Orange Book listings. With sufficient information not provided in the prompt, a complete and accurate patent-by-patent dataset cannot be produced.
Which drugs sit in ATC D11AH (excluding corticosteroids) and who sells them?
Answer (high-level): D11AH typically covers non-steroidal topical dermatologic anti-inflammatory and itch-modulating agents used in dermatitis phenotypes. The market is split between branded pioneers and multiple localized generic or near-generic competitors, with pricing pressure increasing after formulation patents expire and after label expansions that enable broader payer coverage.
How is D11AH demand segmented across dermatitis types?
Demand is usually segmented by:
- Atopic dermatitis adjuncts (where steroid avoidance is a formulary lever)
- Seborrheic dermatitis and facial dermatitis niches
- Irritant or allergic contact dermatitis where non-steroidal anti-inflammatory options are needed
- Eczema-like dermatitides where long-term steroid-sparing strategies are used
What delivery formats dominate?
- Creams and ointments (baseline)
- Gels/lotions (hair-bearing and facial use patterns)
- Foams (scalp preference)
- Prescription-only versus OTC-adjacent pathways in some territories
What patents protect non-steroidal dermatitis agents under ATC D11AH?
Answer (patent types): Protection tends to cluster into three buckets: (1) composition-of-matter for active ingredients or close analogs, (2) formulation/vehicle patents, and (3) method-of-use patents for dermatitis phenotypes, dosing regimens, and steroid-sparing claims. For established actives, estate strength is often carried by formulation improvements and dosing instructions rather than by new actives.
Composition-of-matter: when do they matter most?
- New chemical entities (NCEs): strongest early estate, with 20-year term from earliest effective filing.
- Reformulations and prodrugs: may introduce new compositions or salt/polymorph claims, extending term for specific embodiments.
Formulation patents: where most “life” extensions occur
Typical claim themes:
- Vehicle systems (oil-in-water vs water-in-oil emulsions)
- Penetration enhancers, skin barrier targeting polymers, and controlled release matrices
- Stabilization of actives against pH/oxidation/temperature cycling
- Targeted delivery to epidermis/follicles
Method-of-use and regimen patents
Common claim approaches:
- Specific dermatitis phenotypes (atopic vs seborrheic vs contact)
- Steroid-sparing dosing intervals
- Treatment timelines (induction vs maintenance)
- Surface/lesion-based dosing instructions (thin layer vs occlusive application)
How many patents cover ATC D11AH products and what jurisdictions matter most?
Answer (estimation logic without a product list): Patent density in topical dermatology is highest in the US and in Europe where filing and enforcement are practical. However, the true “count” depends on whether you measure by:
- Family-level patents (one invention across filings)
- Country-level grants (US only vs multi-jurisdiction)
- Orange Book-listed patents (US regulatory relevance)
- Global litigation portfolios (enforcement count)
Without a mapped list of specific D11AH actives and labeled products, a defensible “how many” cannot be computed.
When does exclusivity end for ATC D11AH non-corticosteroid dermatitis drugs?
Answer (timing mechanics): Exclusivity and patent expiry for dermatology topicals typically hinge on:
- Regulatory exclusivity (New Chemical Entity, New Clinical Investigation, pediatric extensions where applicable)
- Patent term (20-year from earliest effective filing, plus possible adjustments)
- Patent-specific last-to-expire dynamics across formulation and method claims
A class-level “end date” is not meaningful without tying exclusivity to specific NDAs/ANDAs and listed patents per product.
What patent expiration dates drive generic and biosimilar entry risk in D11AH?
Answer (risk drivers): For D11AH-like non-steroidal topicals, generic entry is mainly bottlenecked by:
- Orange Book-listed patents that must be addressed in ANDA filings (for US)
- Formulation patents that are harder to design around without triggering infringement
- Method-of-use patents that can bar “label carve-outs” if the generic seeks to maintain therapeutic equivalence
Biosimilars are generally not central to D11AH unless the class is interpreted to include biologic dermatologic immunotherapies in a way that is not typical for this ATC subgroup. A biosimilar risk map must be product-specific.
Which companies are likely challenging D11AH patents via Paragraph IV in the US?
Answer (mechanism): Paragraph IV challenges are common where the branded product has multiple listed patents, particularly formulation or method-of-use patents, and where generics can credibly market at-launch with a carve-out or non-infringing label. Identifying specific filers and challenge targets requires product-level Orange Book extraction.
What is the Orange Book status of ATC D11AH dermatitis non-corticosteroid drugs?
Answer (how Orange Book is used): For US commercialization, the Orange Book controls:
- Which patents are listed for a specific NDA
- The “patent-protected” time window for an ANDA to enter
- The legal triggers for paragraph IV litigation
A definitive Orange Book table cannot be produced without the list of D11AH active ingredients and the tied NDA numbers.
What formulation patents are most likely to block generic launches of dermatitis topicals?
Answer (common blockers):
- Patents claiming specific excipient ranges and emulsifier blends
- Controlled release matrices and rheology-modifier patents
- Stabilization and pH-buffer system patents ensuring shelf-life
- Manufacturing process patents for the formulation embodiment
These create design-around complexity because a generic must prove bioequivalence while navigating infringement risk against vehicle-specific claims.
What method-of-use patents affect label design and steroid-sparing claims?
Answer (label risk):
- Regimens that include steroid-sparing sequencing or maintenance cycles
- Phenotype-linked indications, such as atopic dermatitis severity thresholds
- Dose-frequency claims that are hard to replace without losing therapeutic equivalence
Designing a generic label that avoids infringement can reduce payer reimbursement if the carve-out narrows “treatable” conditions.
How does ATC D11AH compare with ATC D11AX and other dermatitis classes on IP and competition?
Answer (competitive structure):
- D11AX (other dermatologicals) and other sub-classes frequently include newer actives with stronger composition IP earlier in the lifecycle.
- D11AH tends to rely more on formulation and regimen stewardship once actives mature.
A product-to-product comparison requires a defined set of labeled products across sub-classes.
What patent litigation trends exist for non-steroidal dermatitis agents?
Answer (litigation patterns):
- Early-life litigation: when composition and core formulation patents still control
- Mid-life: formulation and method-of-use disputes after generic “shelf” timelines approach
- Resolution: settlements often shift entry rather than invalidate patents, producing “delayed generic” schedules
A litigation docket map requires product identifiers.
What settlement agreements typically delay generic entry in dermatology topicals?
Answer (settlement mechanics):
- “Covenant not to sue” tied to a calendar entry date
- License for specific formulations with royalty or exclusivity for a limited period
- Label carve-outs that limit indications and dosing instructions
Settlement specifics are case-dependent and must be pulled from court filings tied to product-NDA families.
Regulatory pathway: how do FDA approvals interact with patent strategy for D11AH?
Answer (regulatory strategy):
- ANDA strategy: address listed patents via paragraph IV or carve-out labels
- Risk management: avoid infringement of vehicle and method claims
- Launch planning: coordinate with earliest possible “no-infringement” date, not just earliest patent expiry
Again, this must be grounded in the Orange Book and FDA approval history per product.
Commercial market dynamics: what drives pricing, volume, and switching in D11AH?
Answer (commercial drivers):
- Formulary placement: payer preference for steroid-sparing options
- Safety perception and patient adherence: tolerability drives repeat use
- Switching costs: device-like dosing (foams/lotions) and clinician trust
- Promotional cycles: branded remissions tied to seasonal dermatitis patterns
Patent expiration affects these indirectly through competitive entry velocity and payer confidence in generic substitution.
Key takeaways
- ATC D11AH’s patent strategy in non-corticosteroid dermatitis is dominated by formulation and method-of-use IP, which can slow generic launches even after core active patents age out.
- Exclusivity and patent expiry must be computed product-by-product using NDA/Orange Book data; class-level timelines are not actionable for litigation or licensing.
- Competitive entry risk is primarily tied to which patents are Orange Book-listed and what embodiment-specific vehicle or regimen claims cover.
FAQs
- How do formulation patents in topical dermatology affect ANDA design-around strategies?
- What Orange Book-listed patent types most often trigger paragraph IV litigation for topical dermatitis drugs?
- How do label carve-outs interact with method-of-use patent enforcement in dermatitis indications?
- What is the typical settlement structure for delayed generic entry in dermatology topicals?
- How does pediatric or exclusivity extension influence launch timing for non-steroidal dermatitis agents?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drug Approval Reports / Application information (NDA/ANDA/BLA). U.S. Food and Drug Administration.
- U.S. Patent and Trademark Office. Patent term basics and adjustments (PTA) guidance. USPTO.
More… ↓
